Literature DB >> 15297065

Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type.

Anne-Cécile Rimaniol1, Gabriel Gras, François Verdier, Francis Capel, Vladimir B Grigoriev, Fabrice Porcheray, Elisabeth Sauzeat, Jean-Guy Fournier, Pascal Clayette, Claire-Anne Siegrist, Dominique Dormont.   

Abstract

Aluminum hydroxide (AlOOH) has been used for many years as a vaccine adjuvant, but little is known about its mechanism of action. We investigated in this study the in vitro effect of aluminum hydroxide adjuvant on isolated macrophages. We showed that AlOOH-stimulated macrophages contain large and persistent intracellular crystalline inclusions, a characteristic property of muscle infiltrated macrophages described in animal models of vaccine injection, as well as in the recently described macrophagic myofasciitis (MMF) histological reaction in humans. AlOOH-loaded macrophages exhibited phenotypical and functional modifications, as they expressed the classical markers of myeloid dendritic cells (HLA-DR(high)/CD86(high)/CD83(+)/CD1a(-)/CD14(-)) and displayed potent ability to induce MHC-II-restricted antigen specific memory responses, but kept a macrophage morphology. This suggests a key role of macrophages, in the reaction to AlOOH-adjuvanted vaccines and these mature antigen-presenting macrophages may therefore be of particular importance in the establishment of memory responses and in vaccination mechanisms leading to long-lasting protection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297065     DOI: 10.1016/j.vaccine.2004.01.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 2.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

3.  Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Xu Li; Amber N Taylor; Yan-Chun Shi; Zhengrong Cui
Journal:  Vaccine       Date:  2016-05-05       Impact factor: 3.641

4.  Effect of freezing on recombinant hepatitis E vaccine.

Authors:  Kelei Li; Fangyu Dong; Fan Gao; Lianlian Bian; Shiyang Sun; Ruixiao Du; Yalin Hu; Qunying Mao; Haifa Zheng; Xing Wu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

5.  Adjuvant effects of aluminium hydroxide-adsorbed allergens and allergoids - differences in vivo and in vitro.

Authors:  B Heydenreich; I Bellinghausen; L Lund; H Henmar; G Lund; P Adler Würtzen; J Saloga
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 6.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

Review 7.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

8.  Macrophage- and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses.

Authors:  Olivier Epaulard; Lucille Adam; Candice Poux; Gerard Zurawski; Nina Salabert; Pierre Rosenbaum; Nathalie Dereuddre-Bosquet; Sandra Zurawski; Anne-Laure Flamar; Sangkon Oh; Gabrielle Romain; Catherine Chapon; Jacques Banchereau; Yves Lévy; Roger Le Grand; Frédéric Martinon
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

Review 9.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

10.  T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection.

Authors:  Karen Smith Korsholm; Rune V Petersen; Else Marie Agger; Peter Andersen
Journal:  Immunology       Date:  2009-07-14       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.